Skip to main content
. 2011 Jun 16;9:93. doi: 10.1186/1479-5876-9-93

Table 1.

List of useful or promising analyses, in addition to CD4+saurus Rex testing, so far unaccounted for in clinical trial validation but potentially relevant in every-day patient management and clinical decisions

What to test Who and When Possible use/interpretation Ref.
PBMC
PD1+DR+ Ki67+CD4+
Ki67+PD-1+CD4+Treg
Th17 cytokine profile 		Before cART in adv.naive and AIDS-presenter pts Increase. Predict likelihood of IRIS. Diagnosis of IRIS (uppon symptoms [59]
Plasma TNF-a, IL-4, IL-17, VEGF, G-CSF, GM-CSF, CCL2(MCP-1) pt.with cryptococcal meningitis Increase. Predicts high risk of IRIS [60]
PBMC
CD56bright NK cells
NKp30+CD56+, NKp46+CD56+ NK cells 		Before Voluntary or CD4+guided Treatment interruption Increase. Advise against interruption for risk of rapid CD4 decrease when markers are increased [43]
PBMC
CD4+/62L+/RA+
CD8+/CD38+/DR+
CD8+/62L+/RA+ 		Wk16-24 of cART - Adolescents Increase. Risk of Virological Failure after initial response [61]
PBMC
HLA-Bw4 (incl.HLA-B*57, HLA-B*27) 		HIV infection, At first diagnosis Presence. Defines lower risk of progression, chances of Elite Controlling, slow progression, lower VL [62-65]
PBMC
HLA-B*57 + KIR3DS1 		Exposed uninfected partners, Any time Presence. Decreased risk of infection upon HIV exposure [66-68]
PBMC
HLA-B*57 + KIR3DL1high 		Exposed uninfected partners, Any time Presence. Decreased risk of infection upon HIV exposure [69]
HLA-B*57 HIV-Infected, Before cART start Presence. Defines adverse reaction to Abacavir [70]
CCR5-∂32, CCR2-64I At diagnosis. Presence. Slower disease progression, lower VL [71]
Before cART Less time to undetectable VL, decreased risk of AIDS [72,73]
CD127+CD4+ T cells Before cART Decrease. Immunological non-response to cART [49,51,74]
CD127+CD4+ and/or CD127+CD8+ T cells Before Voluntary or CD4+guided treatment interruption Increase. Directly correlated with the length of treatment interruption [75]